Structural Formula (Image 01)
Levetiracetam Injection
Product Images NDC 43547-454
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43547-454). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Image 02)
The given text represents the results of a study comparing the effectiveness of placebo versus two different doses of Levetiracetam. The percentages likely represent the percentage of participants who showed improvement in their condition. The text indicates that the two Levetiracetam doses (1,000 mg/day and 3,000 mg/day) were statistically significant in their effectiveness compared to the placebo. However, without further context, it is difficult to determine the nature of the condition being treated and the full implications of the results.*
Figure 2 (Image 03)
This table shows the percentage of patients in four different groups: placebo, 1,000 mg/day Levetiracetam, and 2,000 mg/day Levetiracetam. The asterisks indicate that there were statistically significant differences between the placebo group and one or both of the Levetiracetam groups.*
Figure 3 (Image 04)
This is a statistical summary of a study where the effectiveness of Levetiracetam 3,000mg/day was compared with placebo in 104 and 180 participants, respectively. The percentages mentioned may represent the efficacy of the drug and the comparison with placebo, but without additional context, it is not possible to interpret them. However, it is noted that the Levetiracetam group had statistically significant results compared to the placebo group.*
Figure 4 (Image 05)
The text describes the results of a clinical trial that compared the effectiveness of a drug called Levetiracetam versus a placebo in a group of 101 individuals. The numbers "44.6%" and "19.6%" could refer to the percentage of participants who experienced a specific outcome or improvement. The text also states that the difference between Levetiracetam and the placebo was statistically significant, suggesting that the drug was more effective than the placebo for treating a particular condition.*
Figure 5 (Image 06)
Figure 6 (Image 07)
This is a table showing the results for a comparison between Placebo and Levetiracetam, with N representing the sample size. There is a statistically significant difference between the two groups, but the exact nature of the comparison is not provided.*
Carton Label 1 (Image 08)
This is a description of a medication called Levetiracetam Injection. The National Drug Code (NDC) is provided as 43547-454.10, and it comes in 10 single-dose vials. The medication has a concentration of 500 mg/5 mL (100 mg/mL), and it is to be used only for intravenous administration after being diluted.*
Vial Label 1 (Image 09)
This is a description of a drug called Levetiracetam. It is available in a single-dose vial size of 5L and is an injection. The drug has been distributed by Solco Healthcare US, LLC and was made in China. However, specific information regarding the dosage and usage of the drug is not available from the given text.*
Carton Label 2 (Image 10)
Each vial of medication contains 500 mg of levetiracetam along with other ingredients like sodium acetate trihydrate and sodium chloride. It is recommended for intravenous use only and must be diluted before admin. The medication should be stored at a controlled room temperature within a certain range. It is manufactured by Zhefing Hushai Pharmaceutical Co. Ltd. in China and distributed in the USA by Solco Healthcare Inc. The dosage guidelines are listed on the package insert.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
